The stock of Cellebrite DI Ltd (NASDAQ: CLBT) has decreased by -1.63 when compared to last closing price of 20.04. Despite this, the company has experienced a -7.67% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-25 that TYSONS CORNER, Va. and PETAH TIKVA, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) — {{DATELINECITY_DATE_GLOBENEWSWIRE_BUG} Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the Company will participate in the upcoming UBS Global Technology and AI Conference. Relevant details include:
Is It Worth Investing in Cellebrite DI Ltd (NASDAQ: CLBT) Right Now?
The 36-month beta value for CLBT is at 1.51. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CLBT is 86.02M, and currently, shorts hold a 1.69% of that float. The average trading volume for CLBT on December 13, 2024 was 1.30M shares.
CLBT’s Market Performance
CLBT’s stock has seen a -7.67% decrease for the week, with a 10.68% rise in the past month and a 12.52% gain in the past quarter. The volatility ratio for the week is 4.68%, and the volatility levels for the past 30 days are at 3.88% for Cellebrite DI Ltd The simple moving average for the last 20 days is -0.63% for CLBT stock, with a simple moving average of 36.89% for the last 200 days.
Analysts’ Opinion of CLBT
Many brokerage firms have already submitted their reports for CLBT stocks, with Needham repeating the rating for CLBT by listing it as a “Buy.” The predicted price for CLBT in the upcoming period, according to Needham is $13.50 based on the research report published on March 28, 2024 of the current year 2024.
BofA Securities gave a rating of “Buy” to CLBT, setting the target price at $12 in the report published on February 16th of the current year.
CLBT Trading at 4.44% from the 50-Day Moving Average
After a stumble in the market that brought CLBT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.24% of loss for the given period.
Volatility was left at 3.88%, however, over the last 30 days, the volatility rate increased by 4.68%, as shares surge +9.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.03% upper at present.
During the last 5 trading sessions, CLBT fell by -7.73%, which changed the moving average for the period of 200-days by +64.58% in comparison to the 20-day moving average, which settled at $19.84. In addition, Cellebrite DI Ltd saw 127.63% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLBT starting from Aliazar Keinan, who proposed sale 19,385 shares at the price of $19.89 back on Dec 11 ’24. After this action, Aliazar Keinan now owns shares of Cellebrite DI Ltd, valued at $385,568 using the latest closing price.
NADINE BAUDOT-TRAJTENBERG, the Director of Cellebrite DI Ltd, proposed sale 619 shares at $20.00 during a trade that took place back on Dec 10 ’24, which means that NADINE BAUDOT-TRAJTENBERG is holding shares at $12,380 based on the most recent closing price.
Stock Fundamentals for CLBT
Current profitability levels for the company are sitting at:
- 0.15 for the present operating margin
- 0.84 for the gross margin
The net margin for Cellebrite DI Ltd stands at -0.82. The total capital return value is set at 0.16. Equity return is now at value -188.50, with -57.30 for asset returns.
Currently, EBITDA for the company is -64.8 million with net debt to EBITDA at 2.96. When we switch over and look at the enterprise to sales, we see a ratio of 10.32. The receivables turnover for the company is 4.11for trailing twelve months and the total asset turnover is 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.81.
Conclusion
In conclusion, Cellebrite DI Ltd (CLBT) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
